EXACT Therapeutics closes the latest fundraising round at NOK 145 million, including a NOK 77 million investment from GE Healthcare in a new strategic collaboration. The funds will go to the ENACT phase II study in locally advanced pancreatic cancer.

“This is planned as a one-arm study, where the company wants to investigate the efficacy and safety of Acoustic Cluster Therapy (ACT) in combination with Standard of Care treatment in first line locally advanced/regional or borderline resectable pancreatic cancer patients. We have planned for 25 patients, where the first three are a safety run-in (expected results mid-2025). We expect to have an interim read-out in first half of 2026, and final results first half of 2027,” says Per Walday, CEO of EXACT Therapeutics.

Related article

EXACT-Tx announces placement of NOK 25 million share issue

EXACT Therapeutics has announced that a private placement has been successfully placed through an allocation of 2,083,333 0ffer shares, at a subscription price of NOK 12 per offer share for total gross proceeds of NOK 25 million. “This financing has been completed without any significant discount to the market price, and we are excited and […]


Collaboration with GE Healthcare

GE Healthcare is both a cornerstone investor in the recent private placement and a strategic collaboration partner for EXACT’s upcoming clinical studies.

“We will work together with GE Healthcare to develop the ultrasound equipment and software needed for the next clinical studies within abdominal cancers, and, ultimately, commercialisation of ACT. GE Healthcare is a global market leader in ultrasound equipment, which means that their equipment is to be found in hospitals all over the world,” says Walday.

Source: Oslo Cancer Cluster